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Biomaterials (composites and blends) play a major role in the health of modern society. This paper reports on 
the preparation and characterization of polyvinylidene fluoride (PVDF) and hydroxyapatite (HAP) composites, 
analyzing the incorporation of HAP in PVDF and investigating their mechanical properties and cytotoxicity 
(biocompatibility) for use in bone restoration and filling. The material was prepared in film form by the casting 
method. PVDF pellets were dissolved in dimethylacetamide (DMA), a HAP/DMA emulsion was prepared. The 
materials were mixed in proportions of 100/00, 90/10, 80/20, 70/30, 60/40, 50/50, 40/60, 30/70 in weight and left to 
dry in an oven, resulting in homogeneous, flexible films which were characterized by scanning electron microscopy 
(SEM), energy dispersive spectroscopy (EDS), X ray diffractometry (XRD), contact angle measurement, and by 
mechanical and cytotoxicity tests.
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1. Introduction
Numerous health-related studies have revealed an ever-grow-
ing search for substances to replace bony parts lost in traumatic 
or nontraumatic events, and metals have been widely used in the 
majority of bone implants. However, the use of metallic materials 
in the human body has given rise to a variety of problems involving 
corrosion, type of wear, and/or negative tissue reaction1. In the search 
for bioactive protheses, improved materials containing hydroxyapatite 
(HAP) have aroused interest in innumerable researches2. Composite 
materials that favor bone formation in the injured site have been 
exhaustively studied. Biodegradable polymers, artificial bone cells 
and morphogenetic proteins with HAP loads have been investigated 
in the formation of natural bones3-7.
In this context, polyvinylidene fluoride (PVDF) membranes 
have been studied for various applications8-12, but the literature lacks 
reports about the use of PVDF in the regeneration of bony tissue. 
With regard to the anti-bacterial property of PVDF membrane13, 
this study investigated the maximum incorporation of HAP in this 
type of membrane and analyzed the results of the assays and tests 
considered basic for the application of PVDF/HAP composites as 
barriers against bone defects.
In addition to examining the physicochemical properties of these 
types of membranes, their biocompatibility must be ascertained since 
they are intended for use in bone tissue regeneration processes. The 
first in vitro biocompatibility test is a cytotoxicity assay. After verify-
ing that the material is devoid of toxicity, further studies and assays 
must be carried out in each stage of the production process to confirm 
its biocompatibility up to the end product.
2. Materials and Methods
2.1. Preparation of the composites
The composites were prepared by dissolving PVDF pellets in 
dimethylacetamide (DMA) in a 50 mL glass beaker under continu-
ous agitation and a controlled temperature of 100 °C. A HAP/DMA 
emulsion was then prepared by agitation without heating in another 
50 mL glass beaker. After complete dissolution of the PVDF, the 
HAP emulsion was added, maintaining the temperature and agitation 
until the mixture attained the necessary viscosity, at which point it 
was poured onto a 60 mm glass Petri dish. The mixture was then 
oven-dried at 110 °C for 4 hours to eliminate the DMA solvent. 
The resulting PVDF/HAP films, prepared in proportions of 100/00, 
90/10, 80/20, 70/30, 60/40, 50/50, 40/60, 30/70 in weight (or %), 
were homogeneous and flexible.
2.2.  Characterization of the composites
The properties of the PVDF/HAP composites were examined by 
scanning electron microscopy (SEM), energy dispersive spectroscopy 
(EDS), X ray diffractometry (XRD), contact angle measurement, and 
mechanical and cytotoxicity assays. The samples for mechanical and 
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cytotoxicity assays were irradiated using a Co-60 gamma ray source 
with a dosage of 25 kGy to ascertain the possible interference of 
structural modifications in their mechanical properties and to sterilize 
the samples for the cytotoxicity assay of biocompatibility.
2.2.1. Scanning electron microscopy (SEM)
Samples of PVDF/HAP composites in proportions of 100/00 and 
60/40 (in weight) were analyzed by SEM and EDS. The surfaces of 
these samples were covered with a thin carbon film to preserve the 
topographies of the original manufacturing process. The purpose of 
this analysis was to observe the heterogeneity of the surface texture 
by SEM (Phillips XL-30).
2.2.2. Energy dispersive spectroscopy (EDS)
As explained under item 2.2.1, the samples were exposed to 
EDS X ray of the largest possible surface area to obtain the most 
general representative spectrum for each sample in order to analyze 
its chemical elements.
2.2.3. X ray diffractometry (XRD)
Powder X ray data were collected in the 2θ interval from 23 to 
100°, in 5s 0.01° steps, using a SIEMENS D5000 diffractometer 
with copper radiation monocromatized by a graphite crystal. The 
diffractometer was set at 40 kV and 30 mA.
2.2.4. Contact angle measures
The hanging drop method was used to measure the contact 
angle (θ) on the surface of PVDF/HAP samples, using a contact 
angle meter (TATEC Cam-micron goniometer). The contact angle 
measurements were taken at room temperature in 75% relative air 
humidity, since the θ varies only slightly with temperature, accord-
ing to Adam14, who found no detectable variations in the water in 
several solid hydrocarbonates in a 20 to 35 °C interval. To establish 
the balance of the forces involved, the contact angle reading was 
obtained 20 seconds after deposition of the drop on the surface of 
the samples. Each θ value corresponds to the average of 4 measure-
ments, with a maximum deviation of ±2. The measurements were 
taken from samples presenting the best surface regularity, since this 
kind of analysis requires uniform surfaces (little roughness) to ensure 
the most reliable contact angle measures are obtained.
2.2.5. Mechanical testing
The PVDF/HAP films were tensile tested to determine their 
mechanical behavior. Three test specimens were tested in each of the 
following proportions: 100/00, 70/30 and 60/40 (in weight) and the 
films were tested with and without irradiation. The tensile tests were 
carried out in an Instron 4400 universal mechanical testing machine, 
with a load cell corresponding to 50 kgf, using a crosshead movement 
testing speed of 5 mm/min. The ultimate strength and total strain of 
the film were determined based on the stress-strain curves resulting 
from the tensile tests.
2.2.6. Cytotoxicity assay
The cytotoxicity assay is an in vitro method to verify the toxicity 
of materials. This assay was carried out according to the ISO 1099315 
standard, whose methodology is described in previous papers16-17. A 
monolayer cell line of NCTC clone 929 obtained from the American 
Type Culture Collection (ATCC) was used in 96 microplate wells, to 
which were added serially diluted extracts of PVDF and PVDF/HAP 
membrane samples. The extracts were obtained by immersing the 
membranes in a flask containing MEM (minimum Eagle’s medium) 
cell culture medium with 5% calf fetal serum and nonessential amino 
acids, which was incubated at 37 °C for 24 hours. PVC pellets were 
used as negative control and the extract was obtained in the same 
way as the membranes. A 0.02% phenol solution was used as posi-
tive control and received the same treatment as the extract dilution. 
The controls served to verify the performance of the assay; a posi-
tive control must be a material that causes toxicity while a negative 
control must be nontoxic. The cytotoxic effect of each material was 
measured based on the percentage of viable cells in contact with the 
extract of the tested material, and quantitatively assessed by measur-
ing the uptake of neutral red by the viable cells. The optical densities 
(OD) were measured in a microplate ELISA reader (Tecan Sunrise 
spectrophotometer) with a 540 nm filter, calculating the percent of 
cell viability in relation to the control cell. The cytotoxicity index, 
represented by IC50% in the viability curves, was obtained by plotting 
the percent of viable cells against the extract concentration. The 
cytotoxicity index represents the concentration of extract that kills 
or injures 50% of the cell population in the assay.
3. Results and Discussion
The maximum amount of hydroxyapatite incorporated into the 
PVDF polymer was 40%. This amount does not cause saturation 
of the polymeric matrix and the HAP appears on the surface of the 
membrane in the form of powder. In the PVDF/HAP 30/70 composi-
tion, the polymeric matrix was unable to support the high load. The 
film-composite was not formed and most of the HAP settled on the 
bottom of the glass plate.
3.1. Scanning electron microscopy (SEM)
Figure 1 shows SEM images magnified 500 and 5000 times. 
Note the PVDF polymer with a globular structure and porous regions 
between the globes. The PVDF/HAP composites showed the HAP 
phase partially filling the original porous spaces of the pure PVDF.
According to Sheldon18, the filler phase (in this case HAP) of a 
polymeric composite can act as a crystal-nucleating agent (or, in rare 
cases, as an anti-nucleant), affecting the size or the perfection of the 
polymer crystal. The presence of HAP to the PVDF matrix appears 
to modify the polymer grain formation process, altering the size and 
morphology of the pores.
3.2. Energy dispersive spectroscopy (EDS)
The EDS spectrum in Figure 2 shows the main chemical elements 
of the PVDF membranes of composition 100/00 and 60/40. These 
elements were identified as carbon and fluorine originating from the 
PVDF structure, and as calcium (Ca) and phosphorus (P) originating 
from the incorporated HAP.
A semi-quantitative relationship of the chemical elements can be 
calculated based on the their peak sizes in the spectrum. The Ca/P 
relationship of HAP is usually 1.65 but the one we observed was 1.15. 
This difference may indicate a chemical reaction between HAP and 
PVDF during the synthesization process. This issue can be clarified 
by X ray Diffraction and/or Fourier Transform Infrared techniques.
3.3. X ray diffractometry (XRD)
The successful incorporation of HAP in the PVDF membranes 
was confirmed by XRD. Figure 3 shows the X ray diffraction pat-
terns of PVDF/HAP composites in the ratio of 100/00 (thick line in 
the graph) and 60/40 (thin line) and the HAP XRD patterns (upward 
pointing triangle - PDF n. 86-740). According to Lovinger19, PVDF 
presents Bragg peak positions at 2θ equal to 20°, 27° and 40°. As 
the diffractogram in Figure 3 demonstrates, the XRD of pure PVDF 
membrane presented characteristic diffraction patterns, indicating 
that the polymer was successfully formed. A comparison of the 
Vol. 10, No. 3, 2007 Characterization of PVDF/HAP Composites for Medical Applications 249
Acc.V Spot Magn Det WD 50 ?m
10.0 kV 4.0 500x SE 10.8 PVDF 100/00
Acc.V Spot Magn Det WD 5 ?m
10.0 kV 4.0 5000x SE 10.8 PVDF 100/00
(a)
Acc.V Spot Magn Det WD 50 ?m
20.0 kV 4.0 500x SE 10.0 60/40 20.0 kV 4.0 5000x SE 10.0 60/40
Acc.V  Spot Magn Det WD 5 ?m
(b)
Figure 1. SEM images magnified 500 and 5000 times: a) pure PVDF membrane; and b) PVDF membrane containing 40% in weight of HAP.
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Figure 2. EDS X ray spectra: a) pure PVDF membrane; and b) PVDF membrane containing 40% in weight of HAP.
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HAP diffraction patterns (upward pointing triangle) and the XRD of 
PVDF/HAP 60/40 (thick line) led us to conclude that the HAP was 
incorporated in the PVDF membrane. The PVDF diffraction patterns 
remain unchanged after the membrane was impregnated with HAP, 
indicating that the PVDF polymeric structure was not modified during 
the synthesis of the composites.
3.4. Contact angle measures
Table 1 presents the values of the contact angles (θ) and the 
respective standard deviations of the PVDF/HAP composites films’ 
surfaces, using distilled water as a measuring liquid.
As can be seen in Table 1, the pure PVDF showed a contact 
angle of 83° while θ tended to increase with addition of increasing 
concentrations of HAP in the polymeric matrix. As the micrographs 
in Figure 1 indicate, this behavior can be attributed to the fact that 
the mineral load modified the polymer grain formation process. The 
size and shape of the pores and the surface characteristics were likely 
modified, reducing the composites’ surface wettability. However, 
in the compositions containing proportions of more than 60/40 the 
contact angle underwent a strong reduction due to saturation of the 
polymeric matrix by the mineral load, which caused the appearance 
of HAP in the form of powder on the surface of the PVDF/HAP films, 
increasing the material’s wettability.
3.5. Mechanical testing
Table 2 shows the ultimate strength and total strain of PVDF/HAP 
film test specimens in the various proportions tested here. The addition 
of HAP clearly reduced both the strength and the strain of PVDF, 
increasing the film’s brittleness and reducing its mechanical strength, 
although it retained a certain degree of flexibility. This was observed 
in the handling of the films when the test specimens were put into the 
testing machine. The test specimens required extra care when they 
were fixed to the grips of the testing machine to prevent them from 
disintegrating during handling. We also found that the flexibility of 
the films declined as the HAP load in the PVDF polymeric matrix 
increased. Table 2 shows that, in general, the tensile tests of the irradi-
ated and non-irradiated samples revealed no significant alteration in 
the samples’ mechanical properties. The only alteration occurred in 
the ultimate toughness of pure PVDF (without added HAP), whose 
values after irradiation dropped from 45.2 to 33.7 MPa. To further il-
lustrate the effect of the addition of HAP on the mechanical properties 
of PVDF films, Figure 4 shows the stress-strain curves obtained from 
the tensile tests of samples containing PVDF/HAP in proportions of 
100/00, 70/30 and 60/40, all non-irradiated.
3.6. Cytotoxicity assay
Table 3 shows the percentage of viable cells in PVDF and PVDF/
HAP membrane samples in the serially diluted extracts obtained from 
the cytotoxicity assay, as well as the negative and positive controls.
The cell viability percentage data compared in the graph against 
the extract concentration (Figure 5) shows the cell viability curves 
of the cytotoxicity assay. All the samples tested here presented the 
same behavior as the negative control, with the viability curves above 
the cytotoxicity index (IC50%) line, indicating no toxic effect. On the 
other hand, the positive control presented a cytotoxic behavior of 
IC50% = 37, indicating that the extract from the positive control, in a 
37% dilution, damaged 50% of the cell population in this assay.
4. Conclusions
The maximum limit of HAP incorporated in PVDF polymeric 
matrix was 40%, forming satisfactorily homogeneous PVDF/HAP 
composites, as indicated by SEM.
Table 1. Contact angle values (θ) of the PVDF/HAP composite film surfaces 
and their respective standard deviations.
PVDF/HAP Composites
100/00 90/10 80/20 70/30 60/40 50/50 40/60
83 ± 2.0° 94 ± 0° 98 ± 0° 110 ± 0° 115 ± 0.5° 41 ± 1.5° 19 ± 3.8°
Table 2. Ultimate strength and total strain obtained from PVDF and PVDF/
HAP tensile test.
Proportion PVDF/HAP Ultimate strength 
(MPa)
Total strain 
(%)
100/00 without irradiation 45.2 ± 1.2 11.3 ± 2.3
100/00 irradiated 33.7 ± 0.3 10.9 ± 0.3
70/30 without irradiation 19.1 ± 1.1 3.9 ± 0.4
70/30 irradiated 19.0 ± 2.8 3.6 ± 0.2
60/40 without irradiation 12.8 ± 1.0 3.5 ± 0.4
60/40 irradiated 10.4 ± 1.6 3.0 ± 0.2
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Figure 3. XRD patterns of PVDF/HAP: 100/00 (sliced line), PVDF/HAP 
- 60/40 (thick line) and HAP phase (upward pointing triangles - PDF 
n. 86-740).
0 2 4 6 8 10 12 14
0
10
20
30
40
50
60/40
70/30
100/00
St
re
ss
 (M
Pa
)
Strain (%)
Figure 4. Stress-strain curves obtained from tensile tests of PVDF/HAP in 
the proportions of 100/00, 70/30 and 60/40.
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Table 3. Percentage of viable cells in PVDF and PVDF/HAP membranes, 
indicated by the cytotoxicity assay using the neutral red uptake method.
Extract 
concentration 
(%)
Cell Viability % ± dp
Negative 
control
Positive 
control
PVDF 
membrane
PVDF/HAP 
membrane
100 99 ± 11 0 ± 0 105 ± 6 90 ± 9
50 107 ± 6 29 ± 1 108 ± 4 101 ± 8
25 100 ± 4 68 ± 12 105 ± 1 125 ± 13
12.5 98 ± 3 89 ± 14 108 ± 4 110 ± 9
6.25 97 ± 3 89 ± 6 108 ± 4 117 ± 9
Figure 5. Cell viability curves of PVDF and PVDF/HAP membranes in the 
cytotoxicity assay using the neutral red uptake method.
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The pores size and morphology in the PVDF matrix was modified 
by the addition of HAP, although the polymer’s crystalline structure 
remained unaltered. This suggests that the incorporated HAP did not 
react with the PVDF matrix during the synthesization process, i.e., the 
composite films were not structurally modified. The addition of HAP 
also rendered the PVDF more brittle and less mechanically resistant, 
despite a certain degree of flexibility in handling, a characteristic that 
declined as the load in the polymeric matrix increased.
The surface wettability of PVDF/HAP composites tended to de-
crease as the percentage in weight of HAP increased in the polymeric 
matrix. This characteristic may represent an obstacle to the material’s 
application in bone implants, since it is known that the greater the 
material’s wettability the better its interaction with the body’s tissues 
and liquids. However, a definitive conclusion concerning this property 
can only be reached by means of in vivo tests, which we plan to carry 
out in future studies.
The PVDF and PVDF/HAP membranes showed no toxicity in the 
first in vitro assay of the biocompatibility study, and are thus potential 
candidates for use in medical and dental applications. However, it 
must be kept in mind that, depending on the application in which these 
membranes are to be used, other biocompatibility tests must be carried 
out, in line with the international standard ISO 1099315.
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